Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 20/20 | 0.99 |
| ▸ | BIRC2 | Q13490 | 10/20 | 0.99 |
| ▸ | BIRC3 | Q13489 | 11/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494898 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL20372810 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL18472982 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL18494900 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL18472981 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL23467275 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL12900680 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL21025826 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| SCHEMBL21341832 | 1.00 | XIAP (0.99) | XIAPBIRC2BIRC3 | |
| Hydrochloric Acid SCHEMBL1273404 | 0.99 | XIAP (1.00) | XIAPBIRC2BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | XIAP 2/4885BIRC2 3/4885BIRC3 7/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | XIAP 23/4885BIRC2 319/4885BIRC3 450/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | XIAP 23/4885BIRC2 319/4885BIRC3 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.